




Hector Fabio Bonilla

Clinical Associate Professor, Medicine - Infectious Diseases

 NIH Biosketch available Online

 Curriculum Vitae available Online

CLINICAL OFFICES

3351 El Camino Real Ste 225

Atherton, CA 94027

Tel (650) 736-5200 **Fax** (650) 497-0754

- **Infectious Disease Clinic**

300 Pasteur Dr Rm L134

Lane Bldg MC 5107

Stanford, CA 94305

Tel (650) 723-6961 **Fax** (650) 725-8418

Bio

BIO

As a young physician at Louisiana State University, Dr. Bonilla focused on the Clinical Management of HIV/AIDS and HCV, two neglected and stigmatized diseases for which effective therapies were in their infancy. While learning the clinical aspects of the two diseases, Dr. Bonilla saw a need to create and organize a support community to promote understanding and management of the conditions. Subsequently, he went to Summa Health System in Akron, Ohio, and he continued his work where he specialized in HIV/HCV as well as in Infectious Diseases Clinical Practice. In addition to teaching medical residents and students, Dr. Bonilla participated in numerous clinical trials and developed clinical research projects. Furthermore, he led the Infection Renal Transplant Program, HIV and HCV clinics, and he participated in several cooperative studies with Case Western Reserve University. Dr. Bonilla's interest in academia led him to the University Of Pittsburgh Medical Center where he was an Assistant Professor, Clinician, and Medical Educator in the Department of Medicine in the Division of Infectious Diseases. Due to his interest in cytokines and immunological responses, Dr. Bonilla became a researcher at ImmunoScience Inc., a biotechnology company in California that works to develop a therapeutic HIV vaccine. Dr. Bonilla's experience of treating HIV/HCV combined with his interest in inflammatory response is the driving force behind his desire to understand ME/CFS. Dr. Bonilla is a strong patient advocate, and he believes in integrated care—care in which physicians communicate and coordinate efforts to deliver the best medical outcome for patients. His ME/CFS patients are his inspiration, and he is committed to continuing research to seek answers to their health challenges.

CLINICAL FOCUS

- Infectious Disease

PATIENT CARE

As a young physician at Louisiana State University, Dr. Bonilla focused on the Clinical Management of HIV/AIDS and HCV, two neglected and stigmatized diseases for which effective therapies were in their infancy. While learning the clinical aspects of the two diseases, Dr. Bonilla saw a need to create and organize a support community to promote understanding and management of the conditions. Subsequently, he went to Summa Health System in Akron, Ohio, and he continued his work where he specialized in HIV/HCV as well as in Infectious Diseases Clinical Practice. In addition to teaching medical residents and students, Dr. Bonilla participated in

numerous clinical trials and developed clinical research projects. Furthermore, he led the Infection Renal Transplant Program, HIV and HCV clinics, and he participated in several cooperative studies with Case Western Reserve University. Dr. Bonilla's interest in academia led him to the University Of Pittsburgh Medical Center where he was an Assistant Professor, Clinician, and Medical Educator in the Department of Medicine in the Division of Infectious Diseases. Due to his interest in cytokines and immunological responses, Dr. Bonilla became a researcher at ImmunoScience Inc., a biotechnology company in California that works to develop a therapeutic HIV vaccine. Dr. Bonilla's experience of treating HIV/HCV combined with his interest in inflammatory response is the driving force behind his desire to understand ME/CFS. Dr. Bonilla is a strong patient advocate, and he believes in integrated care—care in which physicians communicate and coordinate efforts to deliver the best medical outcome for patients. His ME/CFS patients are his inspiration, and he is committed to continuing research to seek answers to their health challenges.

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Infectious Diseases

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, International Collaboration of Endocarditis (ICE) (2010 - present)
- Member, American Society of Microbiology (ASM) (1997 - present)
- Member, Infectious Diseases Society of America (IDSA) (1995 - present)

PROFESSIONAL EDUCATION

- Board Certification: Infectious Disease, American Board of Internal Medicine (1996)
- Fellowship: University of Michigan Infectious Diseases Fellowship (1996) MI
- Board Certification: Internal Medicine, American Board of Internal Medicine (1994)
- Residency: Sinai Grace Hospital Internal Medicine Residency (1994) MI
- Medical Education: Universidad Del Valle (1983) Colombia
- MD, Universidad del Valle School of Medicine, Cali, Colombia , MD (1983)
- Chief Medical Resident, Universidad del Valle , Internal Medicine (1988)
- Visiting Physician, Henry Ford Hospital , Nephrology Department (1990)
- Clinical Research, Sinai Hospital of Detroit , Clinical Research (1991)
- Internship, Sinai Hospital of Detroit , Internal Medicine (1992)
- Residency, Sinai Hospital of Detroit , Internal Medicine Residency (1994)
- ID Fellow, University Of Michigan , Infectious Diseases (1996)

Publications

PUBLICATIONS

- **Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Jacobson, K. B., Rao, M., Bonilla, H., Subramanian, A., Hack, I., Madrigal, M., Singh, U., Jagannathan, P., Grant, P.
2021
- **Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole.** *Journal of translational medicine*
Crosby, L. D., Kalanidhi, S., Bonilla, A., Subramanian, A., Ballon, J. S., Bonilla, H.
2021; 19 (1): 50
- **Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Murugesan, K., Jagannathan, P., Pham, T. D., Pandey, S., Bonilla, H. F., Jacobson, K., Parsonnet, J., Andrews, J. R., Weiskopf, D., Sette, A., Pinsky, B. A., Singh, U., Banaei, et al

2020

- **Beta-Glucanemia after Coronary Artery Bypass Graft Surgery: A Case Report** *JOURNAL OF FUNGI*
Styczynski, A., Bonilla, H., Treynor, E., Shashank, J., Zhang, Y., Finkelman, M.
2018; 4 (4)
- **Beta-Glucanemia after Coronary Artery Bypass Graft Surgery: A Case Report.** *Journal of fungi (Basel, Switzerland)*
Styczynski, A., Bonilla, H., Treynor, E., Shashank, J., Zhang, Y., Finkelman, M.
2018; 4 (4)
- **Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria** *PLOS ONE*
Shields, R. K., Anand, R., Clarke, L. G., Paronish, J. A., Weirich, M., Perone, H., Kieserman, J., Freedy, H., Andrzejewski, C., Bonilla, H.
2017; 12 (3): e0173286
- **Atorvastatin and Fluvastatin Are Associated With Dose-Dependent Reductions in Cirrhosis and Hepatocellular Carcinoma, Among Patients With Hepatitis C Virus: Results From ERCHIVES** *HEPATOLOGY*
Simon, T. G., Bonilla, H., Yan, P., Chung, R. T., Butt, A. A.
2016; 64 (1): 47–57
- **Does Staphylococcus aureus Bacteriuria Predict Clinical Outcomes in Patients With Bacteremia? Analysis of 274 Patients With Staphylococcus aureus Blood Stream Infection** *INFECTIOUS DISEASES IN CLINICAL PRACTICE*
Manandhar, S., Pai, G., Gidwani, H., Nazim, S., Buehrle, D., Shutt, K. A., Bonilla, H.
2016; 24 (3): 151–54
- **Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES** *HEPATOLOGY*
Butt, A. A., Yan, P., Bonilla, H., Abou-Samra, A., Shaikh, O. S., Simon, T. G., Chung, R. T., Rogal, S. S., ERCHIVES Elect Retrieved Cohort
2015; 62 (2): 365–74
- **Patience Is a Virtue: An Argument for Delayed Surgical Intervention in Fulminant Clostridium difficile Colitis** *AMERICAN SURGEON*
Clanton, J., Fawley, R., Haller, N., Daley, T., Porter, J., Paranjape, C., Bonilla, H.
2014; 80 (6): 614–19
- **Dissemination of a pSCFS3-Like cfr-Carrying Plasmid in Staphylococcus aureus and Staphylococcus epidermidis Clinical Isolates Recovered from Hospitals in Ohio** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*
Mendes, R. E., Deshpande, L. M., Bonilla, H. F., Schwarz, S., Huband, M. D., Jones, R. N., Quinn, J. P.
2013; 57 (7): 2923-2928
- **Can a vancomycin assay be utilised to predict plasma telavancin concentrations?** *INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS*
Evans, D. J., Windisch, R. M., Freedy, H. R., Bonilla, H. F.
2013; 41 (5): 495-497
- **Epidemiology and clinical outcomes of patients with Fusobacterium bacteraemia** *EPIDEMIOLOGY AND INFECTION*
Goldberg, E. A., Venkat-Ramani, T., Hewit, M., Bonilla, H. F.
2013; 141 (2): 325–29
- **In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureus** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*
Saravolatz, L. D., Pawlak, J., Johnson, L., Bonilla, H., Saravolatz, L. D., Fakhri, M. G., Fugelli, A., Olsen, W.
2012; 56 (8): 4478–82